Inosine Pranobex
This medicine should always be taken exactly as described in the package leaflet or as directed by a doctor or pharmacist.
AKVIR Strawberry Flavor is an antiviral and immunostimulating medicine (stimulates the immune system).
AKVIR Strawberry Flavor contains the active substance inosine pranobex, which inhibits the growth of pathogenic viruses for humans, including the Herpesgroup, in vitro.
Supportively in people with weakened immunity, in the case of recurring upper respiratory tract infections.
In the treatment of herpes labialis and facial skin caused by the herpes simplex virus (Herpes simplex).
AKVIR Strawberry Flavor can only be used in patients who have been previously diagnosed with a herpes simplex virus infection.
If after 5 to 14 days there is no improvement or the patient feels worse, they should consult their doctor.
Before starting treatment with AKVIR Strawberry Flavor, the patient should discuss it with their doctor or pharmacist.
This medicine should not be used in children under 1 year of age.
The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
In particular, the doctor should be informed about the following medicines, as they may interact with AKVIR Strawberry Flavor:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
This medicine should not be taken during pregnancy and breastfeeding without consulting a doctor. The doctor will assess whether the benefits of taking the medicine outweigh the potential risks.
AKVIR Strawberry Flavor has no influence or negligible influence on the ability to drive and use machines.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
5 ml of the medicine contains 3250 mg of sucrose. This should be taken into account in patients with diabetes.
The medicine contains methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216), which may cause allergic reactions (also late reactions).
The medicine contains 35.16 mg of sodium (the main component of common salt) in each 60 ml of syrup.
This corresponds to 1.76% of the maximum recommended daily intake of sodium in the diet for adults.
This medicine should always be taken exactly as described in the package leaflet or as directed by a doctor or pharmacist. If in doubt, the patient should consult their doctor or pharmacist.
Oral administration.
The dose is determined based on the patient's body weight and depends on the severity of the disease.
The daily dose should be divided into equal single doses taken several times a day.
Adults, including the elderly
The recommended daily dose is 50 mg/kg body weight per day (1 ml per 1 kg body weight per day), taken in 3 or 4 divided doses. The maximum dose is 4 g per day (i.e., 80 ml of syrup per day).
Example:
If the patient weighs 60 kg, according to the recommendation, they should take:
1 ml x 60 kg body weight = 60 ml of syrup per day
The medicine should be taken in 3 or 4 divided doses, so 60 ml should be divided into three parts, i.e., 20 ml in the morning, 20 ml at noon, and 20 ml in the evening.
Children over 1 year of age
The recommended dose is 50 mg/kg body weight per day, usually 1 ml per 1 kg body weight in 3 or 4 equal divided doses per day.
The following table shows the dosage based on the patient's body weight.
* To measure the recommended volume, the polypropylene measuring cup attached to the package should be used.
In the case of recurring herpes infections, it is essential to start treatment during the prodromal period, i.e., pain, tingling, itching, or immediately after the first changes appear.
Duration of treatment
Treatment usually lasts from 5 to 14 days. It is recommended to continue taking the medicine for 1 to 2 days after the symptoms of the disease have subsided.
This medicine should not be used in children under 1 year of age.
So far, no cases of inosine pranobex overdose have been reported. In case of any doubts or discomfort, the patient should immediately consult their doctor.
If a dose of the medicine is missed, it should be taken as soon as possible, unless it is almost time for the next dose. A double dose should not be taken to make up for a missed dose.
Body Weight | Dosage* |
10-14 kg | 3 x 5 ml |
15-20 kg | 3 x 5 to 7.5 ml |
21-30 kg | 3 x 7.5 to 10 ml |
31-40 kg | 3 x 10 to 15 ml |
41-50 kg | 3 x 15 to 17.5 ml |
If treatment is stopped, the expected therapeutic effect may not be achieved, or the symptoms of the disease may worsen.
In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Any medicine can cause an allergic reaction.
Treatment should be stopped and a doctor consultedif any of the following symptoms occur:
The following side effects may occur:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Frequency Not Known(cannot be estimated from the available data):
If any side effects occur, including any side effects not listed in the leaflet, the patient should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the label and carton. The expiry date refers to the last day of the month.
There are no special storage instructions for the medicine.
Store the bottle in the outer packaging to protect it from light.
The shelf life of the medicine after opening the bottle is 6 months.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
A clear and colorless to light yellow syrup with a strawberry flavor.
The medicine is available in a 180 ml glass bottle of orange glass class III, containing 150 ml of syrup. The bottle is closed with an HDPE/LDPE cap with a sealing ring made of foamed LDPE and a guarantee ring made of HDPE, protected against children. A scaled measuring cup made of polypropylene with a capacity of 20 ml and a graduation is attached to the package. The bottle is placed in a cardboard box with an attached patient leaflet.
Zakłady Farmaceutyczne POLPHARMA SA
ul. Pelplińska 19
83-200 Starogard Gdański
Medana Pharma SA
ul. Władysława Łokietka 10
98-200 Sieradz
POLPHARMA Biuro Handlowe Sp. z o.o.
ul. Bobrowiecka 6
00-728 Warsaw
phone: 22 364 61 01
Date of Last Revision of the Leaflet:October 2019
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.